Browsing Tag
Navtemadlin
3 posts
Ipsen closes Kartos Therapeutics acquisition as $1.75bn potential bet moves into Phase III execution
Ipsen completes its Kartos Therapeutics acquisition, adding Phase III navtemadlin under a deal worth up to $1.75bn. See what comes next.
Ipsen agrees €700m Memo Therapeutics deal as acquisition spree accelerates
Ipsen agrees a €700 million Memo Therapeutics deal days after Kartos. Read how the acquisitions reshape its rare-disease pipeline and cash strategy now.
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.